Pliant Therapeutics grants 60,000-share option to director
PLIANT THERAPEUTICS, INC. director Flavia Borellini received a compensatory stock option grant covering 60,000 shares of common stock on July 9, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
PLIANT THERAPEUTICS, INC. director Flavia Borellini received a compensatory stock option grant covering 60,000 shares of common stock on July 9, 2026. The option has an exercise price of $1.13 per share and expires on July 9, 2036. Vesting occurs as 1/36th of the option each month starting on July 9, 2026, subject to her continued service, and all 60,000 option shares are reported as held directly after the award.
Insider Trade Summary
Grant/Award: 60,000 shares
Grant/Award
1 txn
Insider
Borellini Flavia
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1 | 60,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 60,000 contracts (Direct)
Footnotes (1)
- F1. 1/36th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of July 9, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.
Key Figures
Option shares granted: 60,000 shares
Exercise price: $1.13 per share
Expiration date: July 9, 2036
+2 more
5 metrics
Option shares granted
60,000 shares
Stock Option (Right to Buy) granted to director on July 9, 2026
Exercise price
$1.13 per share
Conversion or exercise price for the 60,000-share stock option
Expiration date
July 9, 2036
Expiration of the granted stock option
Shares underlying option
60,000 shares
Underlying common stock tied to the derivative security
Post-transaction derivative holdings
60,000 options
Total stock options held directly by the reporting person after the grant
Key Terms
Stock Option (Right to Buy), exercise price, vesting, derivative security
4 terms
Stock Option (Right to Buy) financial
"security_title is listed as Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price is reported as 1.1300 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"1/36th of the shares subject to such option vest and become exercisable"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
derivative security financial
"transaction_type is derivative for the stock option grant"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did PLIANT THERAPEUTICS (PLRX) report for Flavia Borellini?
PLIANT THERAPEUTICS reported a stock option grant to director Flavia Borellini for 60,000 shares of common stock. The grant is a compensatory award, not an open-market purchase or sale, and is reported as a derivative security.
What is the exercise price and term of the new PLRX stock options granted to Flavia Borellini?
The granted stock option has an exercise price of $1.13 per share and an expiration date of July 9, 2036. This gives the director the right to buy up to 60,000 shares at $1.13 before that date, once vested.
How do the 60,000 PLRX stock options granted to Flavia Borellini vest?
The 60,000-share option vests in 36 equal monthly installments. Specifically, 1/36th vests each month on the monthly anniversary of July 9, 2026, conditioned on Borellini’s continuous service to PLIANT THERAPEUTICS on each vesting date.
How many PLRX derivative securities does Flavia Borellini hold after this Form 4 transaction?
After the reported transaction, Flavia Borellini holds 60,000 stock options directly. These options each relate to one share of common stock and are subject to the $1.13 exercise price and the stated vesting and expiration terms.
Does the PLRX Form 4 show any open-market buys or sells by Flavia Borellini?
The Form 4 shows no open-market purchases or sales. It reports only a compensatory grant/award acquisition of stock options coded as “A,” with no shares bought or sold in the market and net buy/sell direction noted as neutral.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates